Nucleoside Derivatives Inhibiting HCV RNA Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C Virus (HCV) infection are limited, with only two approved therapies available, and there is a lack of effective cell-based viral replication assays or animal models for evaluating nucleoside inhibitors.
Innovation Solution
Development of purine and pyrimidine nucleoside derivatives, specifically compounds of Formula I, which inhibit subgenomic HCV RNA replication in hepatoma cell lines, potentially serving as antiviral drugs for HCV treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogues are used to inhibit HCV replication, then viral replication is inhibited, but the lack of cell-based assays and animal models prevents convenient evaluation of their efficacy
Solution Approach 1:
The patent introduces subgenomic HCV RNA replicons as an intermediary system that bridges the gap between in vitro enzymatic assays and complex whole-cell or animal models. These replicons contain minimal HCV genomic elements necessary for RNA replication but lack genes encoding structural proteins, creating a simplified yet physiologically relevant system for evaluating nucleoside inhibitor efficacy against HCV replication machinery.
Solution Approach 2:
The patent segments the HCV genome into essential replication elements (NS5A, NS5B polymerase, IRES) and non-essential elements (structural proteins, regulatory regions). By constructing subgenomic replicons with only the minimal replication machinery, the system isolates the replication function from other viral processes, enabling focused evaluation of nucleoside inhibitors on RNA synthesis without confounding factors from viral assembly or host cell effects.
2Adaptability or versatility
If only two approved therapies are available for HCV treatment, then treatment options are limited, but developing new nucleoside derivatives requires extensive evaluation infrastructure
Solution Approach 1:
The subgenomic replicon system serves as a simplified intermediary platform that reduces the complexity of evaluating new nucleoside derivatives. By removing non-essential viral genes and focusing only on replication machinery, the system creates a tractable model that can be rapidly screened against candidate compounds without requiring full viral life cycle analysis or complex animal models.
Solution Approach 2:
The patent changes the complexity parameter of the evaluation system by transitioning from whole-virus or animal models to subgenomic replicons. This parameter change reduces biological complexity while preserving the essential replication function, enabling high-throughput screening of nucleoside derivatives with fewer resources and simpler experimental workflows.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit HCV replication, offering a promising therapeutic option for HCV infections by targeting the viral replication machinery, with potential for use in pharmaceutical compositions and administration methods.
Implementation Method 1
most of these nucleoside analogue drugs inhibit viral replication, following conversion to the corresponding triphosphates, through inhibition of the viral polymerase enzymes
Implementation Method 2
This conversion to the triphosphate is commonly mediated by cellular kinases
Data Source
AI summary
The present disclosure relates to the compound of Formula I:Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.